Zuclopenthixol in adults with intellectual disabilities and aggressive behaviours: discontinuation study.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 17470962.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We investigated the effects of zuclopenthixol on aggressive behaviour in patients with intellectual disabilities by randomly withdrawing it after a 6-week period of open treatment. Of the 49 patients responding to the treatment, 39 took part in a randomised withdrawal trial. The placebo subgroup (n=20) showed more aggressive behaviour as indicated by outcomes observed by external raters on the Modified Overt Aggression Scale than did the continuing subgroup (n=19). The results indicate that discontinuation of zuclopenthixolin this population leads to an increase in aggressive behaviour.
Medical subject headings
- Aggression
- Antipsychotic Agents
- Clopenthixol
- Intellectual Disability